<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504413</url>
  </required_header>
  <id_info>
    <org_study_id>30931-A</org_study_id>
    <secondary_id>06-3659-A 01</secondary_id>
    <nct_id>NCT00504413</nct_id>
  </id_info>
  <brief_title>Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone</brief_title>
  <official_title>Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone in Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine to what extent CYP2B6, CYP3A4, and MDR1
      polymorphisms affect the metabolism of methadone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methadone maintenance treatment (MMT) has been used to rehabilitate the opiate addict
      resulting in a higher quality of life for the patient as well as improving social and
      psychological functioning while reducing the overall cost to society. The maintenance dose of
      methadone is highly variable between patients, and drug-drug interactions have been observed
      between methadone and various medications used to treat a variety of diseases. Identification
      and understanding of the enzymes responsible for the metabolism of methadone could
      potentially lead to improved strategy in individualizing methadone dosing and reduce the risk
      of adverse drug interactions.

      Several cytochrome P450 enzymes (CYPs) have been identified and hypothesized to be involved
      in methadone metabolism in vitro, particularly CYP2B6 and CYP3A4. However, the quantitative
      contribution of CYP2B6 and CYP3A4 in the elimination clearance of methadone in vivo remains
      undefined. In addition, methadone is a substrate of the efflux transporter, P-glycoprotein
      (Pgp) at the intestinal mucosa. We are proposing a pilot study in healthy human subjects to
      investigate the following hypotheses:

        1. Pgp limits the gastrointestinal absorption

        2. Inter-subject variations in CYP2B6 and CYP3A4 activities explain the variation in
           methadone clearance in vivo

      This will be accomplished by correlating the pharmacokinetics of methadone and the phenotype
      probes for Pgp (digoxin), CYP2B6 (bupropion) and CYP3A4 (midazolam). We plan to use these
      data to design a human subject study to assess the utility of MDR1 and CYP genotyping in
      predicting the methadone maintenance dose in a cohort of MMT patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Explore if there is a correlation between the areas of the concentration curves of probe substrates for CYP3A4 and/or CYP2B6 and Pgp and the area of the concentration curve of methadone.</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LC-MS assays will be developed to analyze the plasma content of the probe substrates, methadone and their metabolites. Specifically, midazolam, 1-OH midazolam, bupropion, t-butyl-hydroxy bupropion, digoxin, methadone, and EDDP (a methadone metabolite).</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isolate and bank the DNA of the subjects for future genotyping of variant alleles that will be identified in this study to be important in methadone pharmacokinetics.</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Substance-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam(drug), digoxin (drug)</intervention_name>
    <description>Midazolam (2mg po) and digoxin (0.5mg po) will be administered one time, an hour apart. Blood concentration will be collected at various points in an 8 hour period.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion (drug)</intervention_name>
    <description>Bupropion (150mg po) will be administered one time on a separate visit. Blood concentrations will be collected at various points in a 72 hour period.</description>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone (drug)</intervention_name>
    <description>Methadone (10mg po) will be administered at a separate visit 2 weeks after the bupropion visit. The dose is given once. Blood concentrations will be measured at various points in a 72 hour period. Pupil constriction will be measured and urine will be collected during this period as well.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Within 25% of ideal body weight

        Exclusion Criteria:

          -  Pregnant

          -  A prisoner

          -  Enemy, non-combatant

          -  Smoker

          -  Have a history of liver disease

          -  Have a history of heart disease

          -  Have a history of drug abuse

          -  Currently on prescription medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rheem A Totah, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington, Medicinal Chemistry Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean C Dinh, PharmD</last_name>
    <phone>206.616.2775</phone>
    <email>jeandinh@u.washington.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rheem A Totah, PhD</last_name>
    <phone>206.543.9481</phone>
    <email>rtotah@u.washington.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Washington General Clinical Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rheem A Totah, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danny Shen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Terman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristin K Patton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean C Dinh, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Beckett AH, Taylor JF, Casy AF, Hassan MM. The biotransformation of methadone in man: synthesis and identification of a major metabolite. J Pharm Pharmacol. 1968 Oct;20(10):754-62.</citation>
    <PMID>4386743</PMID>
  </reference>
  <reference>
    <citation>Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat. 2002 Sep;23(2):93-105. Review.</citation>
    <PMID>12220607</PMID>
  </reference>
  <reference>
    <citation>Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;(2):CD002209. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD002209.</citation>
    <PMID>12804430</PMID>
  </reference>
  <reference>
    <citation>Brettle RP. HIV and harm reduction for injection drug users. AIDS. 1991 Feb;5(2):125-36. Review.</citation>
    <PMID>2031687</PMID>
  </reference>
  <reference>
    <citation>Ward J, Mattrick R, Hall W. Methadone maintenance treatment and other opioid replacement therapies. Harwood Academic Publishers, Amsterdam. 1998</citation>
  </reference>
  <reference>
    <citation>Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust. 1999 Feb 1;170(3):104-9.</citation>
    <PMID>10065120</PMID>
  </reference>
  <reference>
    <citation>Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000 Apr 1;59(1):17-31. Review.</citation>
    <PMID>10706972</PMID>
  </reference>
  <reference>
    <citation>Stenbacka M, Leifman A, Romelsjö A. The impact of methadone treatment on registered convictions and arrests in HIV-positive and HIV-negative men and women with one or more treatment periods. Drug Alcohol Rev. 2003 Mar;22(1):27-34.</citation>
    <PMID>12745356</PMID>
  </reference>
  <reference>
    <citation>Wong KH, Lee SS, Lim WL, Low HK. Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users. J Subst Abuse Treat. 2003 Apr;24(3):233-9.</citation>
    <PMID>12810144</PMID>
  </reference>
  <reference>
    <citation>Bruera E, Kim HN. Cancer pain. JAMA. 2003 Nov 12;290(18):2476-9. Review.</citation>
    <PMID>14612485</PMID>
  </reference>
  <reference>
    <citation>Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain. 1986 Jun;25(3):297-312.</citation>
    <PMID>3528988</PMID>
  </reference>
  <reference>
    <citation>Manfredi PL, Borsook D, Chandler SW, Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain. 1997 Mar;70(1):99-101.</citation>
    <PMID>9106815</PMID>
  </reference>
  <reference>
    <citation>Mercadante S. Methadone in cancer pain. Eur J Pain. 1997;1(2):77-83; discussion 84-5.</citation>
    <PMID>15102407</PMID>
  </reference>
  <reference>
    <citation>Ripamonti C, Bianchi M. The use of methadone for cancer pain. Hematol Oncol Clin North Am. 2002 Jun;16(3):543-55. Review.</citation>
    <PMID>12170567</PMID>
  </reference>
  <reference>
    <citation>Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 1995;56(2):PL45-50.</citation>
    <PMID>7823756</PMID>
  </reference>
  <reference>
    <citation>Begré S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, Kosel M, Baumann P, Eap CB. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol. 2002 Apr;22(2):211-5.</citation>
    <PMID>11910269</PMID>
  </reference>
  <reference>
    <citation>Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther. 1972 Nov-Dec;13(6):923-30.</citation>
    <PMID>5081605</PMID>
  </reference>
  <reference>
    <citation>Hanna J, Foster DJ, Salter A, Somogyi AA, White JM, Bochner F. Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. Br J Clin Pharmacol. 2005 Oct;60(4):404-13.</citation>
    <PMID>16187972</PMID>
  </reference>
  <reference>
    <citation>Peles E, Schreiber S, Gordon J, Adelson M. Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain. 2005 Feb;113(3):340-6.</citation>
    <PMID>15661442</PMID>
  </reference>
  <reference>
    <citation>Charlier C, Dessalles MC, Plomteux G. Methadone maintenance treatment: is it possible to adapt the daily doses to the metabolic activity of the patient? Ther Drug Monit. 2001 Feb;23(1):1-3.</citation>
    <PMID>11206036</PMID>
  </reference>
  <reference>
    <citation>Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend. 2003 Mar 1;69(2):205-11.</citation>
    <PMID>12609702</PMID>
  </reference>
  <reference>
    <citation>Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93. Review.</citation>
    <PMID>12405865</PMID>
  </reference>
  <reference>
    <citation>Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2000 Nov;50(5):427-40.</citation>
    <PMID>11069437</PMID>
  </reference>
  <reference>
    <citation>Iribarne C, Dréano Y, Bardou LG, Ménez JF, Berthou F. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology. 1997 Feb 14;117(1):13-23.</citation>
    <PMID>9020195</PMID>
  </reference>
  <reference>
    <citation>Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet. 2003;42(9):819-50. Review.</citation>
    <PMID>12882588</PMID>
  </reference>
  <reference>
    <citation>Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004 Jan;16(1):36-44.</citation>
    <PMID>14628297</PMID>
  </reference>
  <reference>
    <citation>Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69.</citation>
    <PMID>15371986</PMID>
  </reference>
  <reference>
    <citation>Moody DE, Walsh SL, Rollins DE, Neff JA, Huang W. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals. Clin Pharmacol Ther. 2004 Aug;76(2):154-66.</citation>
    <PMID>15289792</PMID>
  </reference>
  <reference>
    <citation>Oda Y, Kharasch ED. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther. 2001 Sep;298(3):1021-32.</citation>
    <PMID>11504799</PMID>
  </reference>
  <reference>
    <citation>Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos. 2003 Jun;31(6):742-7.</citation>
    <PMID>12756206</PMID>
  </reference>
  <reference>
    <citation>Boulton DW, Arnaud P, DeVane CL. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther. 2001 Jul;70(1):48-57.</citation>
    <PMID>11452244</PMID>
  </reference>
  <reference>
    <citation>Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, Yan B, Negishi M, LeCluyse EL. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58.</citation>
    <PMID>14977870</PMID>
  </reference>
  <reference>
    <citation>Hesse LM, Sakai Y, Vishnuvardhan D, Li AP, von Moltke LL, Greenblatt DJ. Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. J Pharm Pharmacol. 2003 Sep;55(9):1229-39.</citation>
    <PMID>14604466</PMID>
  </reference>
  <reference>
    <citation>Martin H, Sarsat JP, de Waziers I, Housset C, Balladur P, Beaune P, Albaladejo V, Lerche-Langrand C. Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res. 2003 Apr;20(4):557-68.</citation>
    <PMID>12739762</PMID>
  </reference>
  <reference>
    <citation>Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209. Review.</citation>
    <PMID>15364537</PMID>
  </reference>
  <reference>
    <citation>Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta. 2003 Feb 17;1619(3):243-53. Review.</citation>
    <PMID>12573484</PMID>
  </reference>
  <reference>
    <citation>Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, Eap CB. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005 Dec;78(6):593-604.</citation>
    <PMID>16338275</PMID>
  </reference>
  <reference>
    <citation>Lötsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmöller J, Geisslinger G. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther. 2006 Jan;79(1):72-89.</citation>
    <PMID>16413243</PMID>
  </reference>
  <reference>
    <citation>Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology. 2003 Jul;45(1):122-32.</citation>
    <PMID>12814665</PMID>
  </reference>
  <reference>
    <citation>Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. Review.</citation>
    <PMID>9890159</PMID>
  </reference>
  <reference>
    <citation>de Boer AG, van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol. 2003;43:629-56. Epub 2002 Jan 10. Review.</citation>
    <PMID>12415123</PMID>
  </reference>
  <reference>
    <citation>Fricker G, Miller DS. Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo. Pharmacol Toxicol. 2002 Jan;90(1):5-13. Review.</citation>
    <PMID>12005113</PMID>
  </reference>
  <reference>
    <citation>Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000 Feb;38(2):69-74. Review.</citation>
    <PMID>10706193</PMID>
  </reference>
  <reference>
    <citation>Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins PB, Schuetz E. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther. 2006 Apr;79(4):325-38. Epub 2006 Feb 20.</citation>
    <PMID>16580901</PMID>
  </reference>
  <reference>
    <citation>Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42(1):59-98. Review.</citation>
    <PMID>12489979</PMID>
  </reference>
  <reference>
    <citation>Bouër R, Barthe L, Philibert C, Tournaire C, Woodley J, Houin G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol. 1999;13(4):494-500.</citation>
    <PMID>10456292</PMID>
  </reference>
  <reference>
    <citation>Callaghan R, Riordan JR. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem. 1993 Jul 25;268(21):16059-64.</citation>
    <PMID>8101846</PMID>
  </reference>
  <reference>
    <citation>Störmer E, Perloff MD, von Moltke LL, Greenblatt DJ. Methadone inhibits rhodamine123 transport in Caco-2 cells. Drug Metab Dispos. 2001 Jul;29(7):954-6.</citation>
    <PMID>11408360</PMID>
  </reference>
  <reference>
    <citation>Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 2000 May;92(5):1392-9.</citation>
    <PMID>10781286</PMID>
  </reference>
  <reference>
    <citation>Kharasch ED, Hoffer C, Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol. 2004 May;57(5):600-10.</citation>
    <PMID>15089813</PMID>
  </reference>
  <reference>
    <citation>Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berl). 2004 Apr;173(1-2):132-8. Epub 2004 Jan 8.</citation>
    <PMID>14712343</PMID>
  </reference>
  <reference>
    <citation>Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000 Apr;10(3):187-216. Review.</citation>
    <PMID>10803676</PMID>
  </reference>
  <reference>
    <citation>Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS Jr. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the &quot;Cooperstown cocktail&quot;. Clin Pharmacol Ther. 2000 Oct;68(4):375-83.</citation>
    <PMID>11061577</PMID>
  </reference>
  <reference>
    <citation>Doherty JE, Flanigan WJ, Murphy ML, Bulloch RT, Dalrymple GL, Beard OW, Perkins WH. Tritiated digoxin. XIV. Enterohepatic circulation, absorption, and excretion studies in human volunteers. Circulation. 1970 Nov;42(5):867-73.</citation>
    <PMID>5477259</PMID>
  </reference>
  <reference>
    <citation>Klotz U, Antonin KH. Biliary excretion studies with digoxin in man. Int J Clin Pharmacol Biopharm. 1977 Jul;15(7):332-4.</citation>
    <PMID>892949</PMID>
  </reference>
  <reference>
    <citation>Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2003 Oct;74(4):326-33.</citation>
    <PMID>14534519</PMID>
  </reference>
  <reference>
    <citation>Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos. 2004 Jun;32(6):626-31.</citation>
    <PMID>15155554</PMID>
  </reference>
  <reference>
    <citation>Rosner B. Fundamentals of Biostatistics. Duxbury, 2006.</citation>
  </reference>
  <reference>
    <citation>Whittington D, Sheffels P, Kharasch ED. Stereoselective determination of methadone and the primary metabolite EDDP in human plasma by automated on-line extraction and liquid chromatography mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 5;809(2):313-21.</citation>
    <PMID>15315782</PMID>
  </reference>
  <reference>
    <citation>Jabor VA, Coelho EB, Dos Santos NA, Bonato PS, Lanchote VL. A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Aug 5;822(1-2):27-32.</citation>
    <PMID>15993663</PMID>
  </reference>
  <reference>
    <citation>Tracqui A, Kintz P, Ludes B, Mangin P. High-performance liquid chromatography-ionspray mass spectrometry for the specific determination of digoxin and some related cardiac glycosides in human plasma. J Chromatogr B Biomed Sci Appl. 1997 Apr 25;692(1):101-9.</citation>
    <PMID>9187389</PMID>
  </reference>
  <reference>
    <citation>Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol. 1997 Aug;37(8):737-43.</citation>
    <PMID>9378846</PMID>
  </reference>
  <reference>
    <citation>Allen DM. The prediction sum of squares as a criterion for selecting predictor variables. In University of Ky Dept of Statistics Tech Report 23, 1971</citation>
  </reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2007</study_first_submitted>
  <study_first_submitted_qc>July 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <last_update_submitted>October 11, 2010</last_update_submitted>
  <last_update_submitted_qc>October 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rheem Totah/Assistant Professor, Medicinal Chemistry</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>Metabolic Networks and Pathways</keyword>
  <keyword>Methadone</keyword>
  <keyword>Polymorphism, genetic</keyword>
  <keyword>Cytochrome P-450 Enzyme System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

